PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron

Clin Transl Med. 2022 Apr;12(4):e806. doi: 10.1002/ctm2.806.

Arpan Acharya¹, Anup S Pathania², Kabita Pandey¹, Michellie Thurman¹, Kendra R Vann³, Tatiana G Kutateladze³, Kishore B Challagundala^{2

4}, Donald L Durden^{5

6}, Siddappa N Byrareddy^{1

2

7

8}

¹ Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA.
² Department of Biochemistry and Molecular Biology, University of Nebraska Medical Centre, Omaha, Nebraska, USA.
³ Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado, USA.
⁴ The Child Health Research Institute, University of Nebraska Medical Center, Omaha, Nebraska, USA.
⁵ Division of Pediatric Hematology-Oncology, Department of Pediatrics, Moores Cancer Center, UC San Diego School of Medicine, La Jolla, California, USA.
⁶ Levine Cancer Institute, Charlotte, North Carolina, USA.
⁷ Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Centre, Omaha, Nebraska, USA.
⁸ Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

No abstract available

Publication types